DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gleevec (Imatinib Mesylate) - Current Clinical Trials

 
 



Gleevec Related Clinical Trials

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas [Active, not recruiting]

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients [Terminated]

Therapy of Early Chronic Phase CML With Gleevec [Completed]

Effect of Antacids on Gleevec´┐Ż in Healthy Volunteers [Completed]

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma [Completed]

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG [Completed]

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer [Completed]

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec« Indicated Hematological Disorders. [Terminated]

Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma [Terminated]

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Completed]

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia [Completed]

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia [Completed]

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C [Terminated]

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma [Completed]

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [Completed]

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia [Completed]

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma [Completed]

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) [Completed]

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) [Terminated]

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients [Terminated]

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer [Completed]

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin [Terminated]

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma [Terminated]

Ipilimumab and Imatinib Mesylate in Advanced Cancer [Recruiting]

Gleevec Study for Patients With Ovarian Cancer [Completed]

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST [Completed]

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST [Completed]

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers [Completed]

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma [Completed]

Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease [Completed]

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) [Completed]

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma [Terminated]

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer [Completed]

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma [Completed]

Study of Temzolomide and Gleevec in Advanced Melanoma [Completed]

Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients [Active, not recruiting]

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma [Active, not recruiting]

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator [Active, not recruiting]

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas [Completed]

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis [Completed]

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [Completed]

Imatinib in KIT-negative Systemic Mastocytosis [Active, not recruiting]

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients [Completed]

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Terminated]

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) [Withdrawn]

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) [Completed]

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes [Completed]

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma [Terminated]

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus [Recruiting]

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer [Terminated]

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia [Completed]

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) [Completed]

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP [Completed]

A Study of Nilotinib Versus Imatinib in GIST Patients [Completed]

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Terminated]

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) [Recruiting]

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) [Completed]

Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers [Completed]

Imatinib Mesylate in Treating Patients With Metastatic Melanoma [Completed]

Drug-drug Interaction Study With Metformin and Imatinib [Completed]

Effect of a Proton Pump Inhibitor on Gleevec« in Healthy Volunteers [Completed]

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia [Withdrawn]

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma [Completed]

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy [Completed]

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Completed]

New Individualized Therapy Trial for Metastatic Colorectal Cancer [Completed]

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients [Active, not recruiting]

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer [Completed]

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma [Completed]

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer [Completed]

Imatinib (QTI571) in Pulmonary Arterial Hypertension [Completed]

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery [Completed]

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer [Completed]

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients [Terminated]

Rechallenge of Imatinib in GIST Having no Effective Treatment [Completed]

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure [Completed]

Late Chronic Phase Chronic Myelogenous Leukemia [Completed]

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes [Completed]

A Study of Imatinib and Docetaxel in Prostate Cancer [Completed]

Randomized ph Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib [Completed]

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST [Recruiting]

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor [Completed]

A Global Imatinib and Nilotinib Pregnancy Exposure Registry [Completed]

Imatinib Mesylate in Treating Patients With Recurrent Meningioma [Completed]

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Terminated]

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia [Recruiting]

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL [Not yet recruiting]

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans [Completed]

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia [Recruiting]

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) [Active, not recruiting]

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer [Terminated]

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis [Recruiting]

Imatinib Mesylate in Treating Patients With Myelofibrosis [Completed]

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017